期刊文献+

缬沙坦对高浓度CRP诱导的单核细胞IL-6合成的影响

Effects of Valsartan on Interleukin-6 Synthesis in Monocytes Stimulated by 50mg/L C-reactive Protein
下载PDF
导出
摘要 目的:观察缬沙坦对高浓度C反应蛋白(CRP)诱导的正常人外周血单核细胞合成白细胞介素-6(IL-6)的影响,探讨缬沙坦的抗炎作用。方法:采用密度梯度离心法分离人外周血单核细胞,应用酶联免疫吸附试验分别观察CRP刺激单核细胞产生IL-6的时间及剂量效应,其峰值与缬沙坦抑制剂组比较。结果:CRP刺激单核细胞IL-6合成呈时间依赖性和剂量依赖性,50 mg/L CRP诱导IL-6合成开始的时间是4 h,在24 h达高峰,其峰值是1 204±272 ng/L;仅高浓度缬沙坦(1×10-3mol/L)能抑制50 mg/LCRP诱导的单核细胞IL-6合成。结论:缬沙坦在体外能抑制CRP诱导单核细胞产生IL-6,但这一效果仅在体内并不能达到的高浓度时产生。 Objective:To evalulate the effect of valsartan on interleukin-6 production in human monocytes stimulated by 50 mg/L c-reactive protein(CRP),and assess the influence of valsartan on monocytes inflammatory reaction.Methods:Monocytes were isolated by Ficoll density gradient from blood of healthy volunteers.And ELISA was adopted to measure IL-6 production stimulated by 50 mg/L CRP at 2,4,8,16,24 hours and 50 mg/L CRP at 24 hours,the peak to be compared with that of the group valsartan(1×10^(-6) ~ 1×10^(-3) mol/L).Result:IL-6 could be produced after being stimulated with 50 mg/L CRP at 4 h.The effect of CRP was dose-dependent and time-dependent,reaching peak at 24 h.And the highest level of monocytes IL-6 was 1 204 ± 272 ng/L in CRP group.Valsartan(1×10^(-3) mol/L) inhibited IL-6 production induced by 50 mg/L CRP.Conclusion:Valsartan is able to inhibit IL-6 production induced by 50 mg/L CRP in vitro,but this effect isn,t shown in vivo.
出处 《长江大学学报(自科版)(下旬)》 CAS 2006年第4期260-261,265,共3页 Journal of Yangtze University
基金 长江大学医学院科研基金资助(编号:200304)
关键词 白细胞介素-6 缬沙坦 C反应蛋白 Interleukin-6 Valsartan C-reactive protein
  • 相关文献

参考文献3

二级参考文献16

  • 1孙心.《中华人民共和国药典》(2000年版)简介[J].吉林医学信息,2001,18(3):14-15. 被引量:2
  • 2Yudkin JS, Kumari M, Hmnphries SE, et al . Inflammation, obesity,stress and coronary heart disease: is interldukin-6 the link[J]? Atherosclerosis, 2000, 148:209-214.
  • 3Schiffrin EL. Beyond blood pressttre: the endothelium and atheroscleroe, is progression [ J ]. American Journal of Hypertension, 2002, 15 :115S-122S.
  • 4Ross R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med,1999,340:115-126.
  • 5Watanabe S, Mu W, Kahn A, et al . Role of JAK/STAT pathway in IL6-induced activation of vasctflar smooth rtmscle eens [ J ]. Am J Nephrol, 2004, 24: 387-392.
  • 6Mazer SP, Rabbani LE. Evidence for C-reactive protein's role in(CRP) vascular disease: Atherothrombosis, immmo-regulation and CRP[J]. J Thromb Thrombolysis,2004, 17:95-105.
  • 7Wu L, Iwai M, Nakagami H, et al . Roles of angiotensin Ⅱ type 2 receptor stimulation associated with selective angiotensin Ⅱ type 1 receptor blockade with valsartan in the improvement of inflananation-induced vascular injury[J]. Circulation,2001,104:2716-2721.
  • 8WuL,IwaiM,NakagamiH ,etal.RolesofangiotensinⅡtype2re ceptorstimulationassociatedwithselectiveangiotensinⅡtype1recep torblockadewithvalsartanintheimprovementofinflammation inducedvascularinjury[].Circulation.2001
  • 9PeetersAC,NeteaMG,KullbergBJ ,etal.The effect of renin an giotensinsysteminhibitorsonpro andanti inflammatorycytokinepro duction[].Immunology.1998
  • 10LehrHA,sagbanTA,IhlingC ,etal.Immunopathogenesisofatherosclerosis∶endotoxinacceleratesatherosclerosisinrabbitsonhy percholesterolemicdiet[].Circulation.2001

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部